SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
IMTX

Immatics N.V. (NASDAQ:IMTX)

DE · Delayed Price · Currency is USD
Healthcare · Biotechnology
$5.77-$0.18 (-3.03%)
 
Market cap
$863M
Insider Score
Health Score
Analyst consensus
Listed since
Dec 12, 2018
Market Cap$863.40M-45.6%
Revenue (ttm)$43.44M-48.7%
Net Income-$232.03M-100.2%
EPS-$1.67-92.0%
Shares Out149.64M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume746,747
Open$5.91
Previous Close$5.95
Day's Range$5.71 - $5.95
52-Week Range$5.71 - $12.41
Beta1.35
AnalystsBuy
Price Target$17.67(+206.24%)
Earnings DateMar 4, 2027

About IMTX

Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.

Address
Paul-Ehrlich-Strasse 15, Tübingen, BW, 72076, DE
Market Cap
863 million
Employees
704
Industrial Classification
Biotechnology

Immatics N.V. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
8th Percentile Overall Score
IMTX InsiderScore:45 / 99

Immatics N.V. scored higher than 8% of companies evaluated by InsiderBuying, and ranked 84th out of 110 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Immatics N.V. bought $7.50 million of stock across 1 purchase in the last 90 days, the largest of them $7.50 million.

Stake Increase

The average purchase added about 8% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$138.58K
Bought
$7.50M

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Fair
From IMTX’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-3.03%
5 Days
-8.85%
1 Month
-23.47%
6 Months
-50.34%
1 Year
-45.57%

$IMTX stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in IMTX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by IMTX's directors and management

Net Shares Purchased by Insiders−900k−450k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

IMTX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New IMTX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to IMTX from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in IMTX

SPDWState Street SPDR Portfolio Developed World ex-US ETF$1.21M
KOMPState Street SPDR S&P Kensho New Economies Composite ETF$1.10M
SBIOALPS Medical Breakthroughs ETF$1.06M
CANCTema Oncology ETF$860.00K
ONEQFidelity Nasdaq Composite Index ETF$368.64K
GWXState Street SPDR S&P International Small Cap ETF$345.31K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from IMTX’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
44.8
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
35

News check: Q3 earnings missed revenue estimates with net loss expansion; mixed outlook on stock performance potential despite expectations.

Recent Insider Activity

Buys
1
Sells
1
Buy Value
$7.50M
Distinct Buyers
1

Insider Score Trend Over Time

+12.7 since Sep 24
0255075100Sep 24 — Insider Score 32.1Sep 25 — Insider Score 58.3Sep 26 — Insider Score 57.8Sep 27 — Insider Score 58.0Sep 28 — Insider Score 58.0Sep 29 — Insider Score 57.4Sep 30 — Insider Score 57.3Oct 1 — Insider Score 56.4Oct 2 — Insider Score 49.0Oct 3 — Insider Score 56.1Oct 4 — Insider Score 56.4Oct 5 — Insider Score 56.5Oct 6 — Insider Score 55.7Oct 7 — Insider Score 55.2Oct 8 — Insider Score 54.9Oct 9 — Insider Score 54.8Oct 10 — Insider Score 54.3Oct 11 — Insider Score 55.5Oct 12 — Insider Score 55.6Oct 13 — Insider Score 55.3Oct 14 — Insider Score 55.2Oct 15 — Insider Score 55.1Oct 16 — Insider Score 55.0Oct 17 — Insider Score 54.8Oct 18 — Insider Score 55.2Oct 19 — Insider Score 54.9Oct 20 — Insider Score 55.1Oct 21 — Insider Score 54.9Oct 22 — Insider Score 55.0Oct 23 — Insider Score 54.9Oct 24 — Insider Score 54.8Oct 25 — Insider Score 54.5Oct 26 — Insider Score 54.5Oct 27 — Insider Score 54.6Oct 28 — Insider Score 54.6Oct 29 — Insider Score 54.6Oct 30 — Insider Score 53.6Oct 31 — Insider Score 53.2Nov 1 — Insider Score 53.6Nov 2 — Insider Score 53.8Nov 3 — Insider Score 53.2Nov 4 — Insider Score 53.0Nov 5 — Insider Score 53.0Nov 6 — Insider Score 52.3Nov 7 — Insider Score 51.6Nov 8 — Insider Score 52.5Nov 9 — Insider Score 53.0Nov 10 — Insider Score 52.0Nov 11 — Insider Score 50.7Nov 12 — Insider Score 51.1Nov 13 — Insider Score 50.1Nov 14 — Insider Score 48.6Nov 15 — Insider Score 49.1Nov 16 — Insider Score 49.7Nov 17 — Insider Score 47.7Nov 18 — Insider Score 46.9Nov 19 — Insider Score 45.9Nov 20 — Insider Score 45.1Nov 21 — Insider Score 44.2Nov 22 — Insider Score 44.8Sep 24Oct 23Nov 22

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

TMEDT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF0.65%
SBIOALPS Medical Breakthroughs ETF0.64%
BBCVirtus Biotech Clinical Trials ETF0.53%
CANCTema Oncology ETF0.45%
TSEET. Rowe Price Small Cap ETF0.26%
KOMPState Street SPDR S&P Kensho New Economies Composite ETF0.05%

Weight is the stock’s share of each fund’s holdings.